Education
About Us
Working with TipRanks
Follow Us
Kamada (KMDA)
NASDAQ:KMDA
KMDA Stock Chart & Stats
$8.50
$0.85(12.50%)
At close: 4:00 PM EST
$8.50
$0.85(12.50%)
Day’s Range― - ―
52-Week Range$5.54 - $9.35
Previous CloseN/A
Volume680.22K
Average Volume (3M)75.86K
Market Cap
$498.32M
Enterprise Value$426.37M
Total Cash (Recent Filing)$75.48M
Total Debt (Recent Filing)$11.56M
Price to Earnings (P/E)18.7
Beta0.64
Next Earnings
May 26, 2026EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding57,681,590
10 Day Avg. Volume88,398
30 Day Avg. Volume75,857
Financial Highlights & Ratios
PEG Ratio0.41
Price to Book (P/B)1.52
Price to Sales (P/S)2.09
P/FCF Ratio24.14
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue2.35
Enterprise Value/Gross Profit5.55
Enterprise Value/Ebitda11.23
Forecast
1Y Price Target
$14.00Price Target Upside64.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)<0.01
Revenue Forecast (FY)$648.35K
Bulls Say, Bears Say
Bulls Say
Commercial Portfolio PenetrationAnalyst notes that rising U.S. sales of VARIZIG and KEDRAB together with international strength in KAMRAB and GLASSIA support broader commercial portfolio penetration and revenue growth.
Distribution Expansion And BiosimilarsAnalyst highlights that expansion of the Distribution business and planned biosimilar launches can diversify sales channels and create scalable new revenue streams.
Plasma Collection Vertical IntegrationAnalyst views the ramp of U.S. plasma collection operations, including expected regulatory approval for the San Antonio site, as a means to reduce specialty plasma input costs and add a direct revenue source.
Bears Say
Capital Allocation RiskAnalyst raises concern that capital freed from the discontinued Phase 3 program may be reallocated inefficiently, which could slow acceleration of the existing commercial portfolio.
Clinical Development SetbackAnalyst warns that discontinuation of the AAT Phase 3 clinical trial increases uncertainty around the company’s drug development pipeline and future therapeutic prospects.
Royalty Rate PressureAnalyst notes that a reduced GLASSIA royalty rate from partner Takeda will cut product royalty income and could exert downward pressure on reported revenues.
Kamada News
KMDA FAQ
What was Kamada’s price range in the past 12 months?
Kamada lowest stock price was $5.54 and its highest was $9.35 in the past 12 months.
What is Kamada’s market cap?
Kamada’s market cap is $498.32M.
When is Kamada’s upcoming earnings report date?
Kamada’s upcoming earnings report date is May 26, 2026 which is in 64 days.
How were Kamada’s earnings last quarter?
Kamada released its earnings results on Mar 11, 2026. The company reported $0.068 earnings per share for the quarter, missing the consensus estimate of $0.078 by -$0.01.
Is Kamada overvalued?
According to Wall Street analysts Kamada’s price is currently Undervalued.
Does Kamada pay dividends?
Kamada pays a Notavailable dividend of $0.2 which represents an annual dividend yield of N/A. See more information on Kamada dividends here
What is Kamada’s EPS estimate?
Kamada’s EPS estimate is 0.12.
How many shares outstanding does Kamada have?
Kamada has 57,681,590 shares outstanding.
What happened to Kamada’s price movement after its last earnings report?
Kamada reported an EPS of $0.068 in its last earnings report, missing expectations of $0.078. Following the earnings report the stock price went down -4.576%.
Which hedge fund is a major shareholder of Kamada?
Currently, no hedge funds are holding shares in KMDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kamada Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.00 (64.71% Upside)
$14.00 (64.71% Upside)
Blogger Sentiment
Bullish
KMDA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 256.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.81%
12-Months-Change
Fundamentals
Return on Equity
7.75%
Trailing 12-Months
Asset Growth
1.73%
Trailing 12-Months
Company Description
Kamada
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.
KMDA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with strong revenue growth, increased EBITDA, and successful product launches. However, challenges remain with declining Glacia royalties, below-plan Cytogam sales, and slow clinical trial enrollment.View all KMDA earnings summariesKMDA Stock 12 Month Forecast
Average Price Target
$14.00
▲(64.71% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.52% Mutual Funds
4.15% Other Institutional Investors
93.71% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---